Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Evaxion announces promising clinical Phase 1 data for its personalized cancer…
Positive clinical response as demonstrated in 8 out of 12 patients receiving EVX-01 in combination with a checkpoint inhibitor The study met primary endpoints for tolerability and safety COPENHAGEN, Denmark, May25, 2023(GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, to present promising clinical data from its EVX-01 Phase 1 clinical trial in...
Nasdaq GlobeNewswire
25/05/2023
Evaxion unveils proprietary genetic adjuvant technology to boost the effect of…
Evaxion developed a genetic adjuvant technology that boosts the immune responses of viral, bacterial and cancer vaccines Preclinically validated for both DNA and mRNA vaccines, and ready for clinical testing Anticipated large market potential for DNA and mRNA vaccines against cancer, viral and bacterial diseasesCOPENHAGEN, Denmark, May25, 2023(GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in...
Nasdaq GlobeNewswire
25/05/2023
MDxHealth Announces Results of its Annual and Extraordinary General…
NEWS RELEASE - REGULATED INFORMATION 25 May 2023 , 22:30 CETMDxHealth Announces Resultsof its Annual and Extraordinary General Shareholders' MeetingsIRVINE, CA, and HERSTAL, BELGIUM– 25 May 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (" MDxHealth " or the " Company "), a commercial-stage precision diagnostics company, today held its ordinary annual general shareholders' meeting (" AGM ") and an extraordinary general shareholders'...
Nasdaq GlobeNewswire
25/05/2023
Alkermes Files Definitive Proxy Statement and Issues Letter to Shareholders…
Company Launches www.AlkermesValue.com, Providing Additional Information for Shareholders Company Launcheswww.AlkermesValue.com, Providing Additional Information for Shareholders Alkermes' Board Recommends Shareholders Vote "FOR" Alkermes' Director Nominees on Company'sWHITEProxy Card DUBLIN,May 25, 2023/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) (the Company) today filed its definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) and issued a...
PR Newswire
25/05/2023
Jazz Pharmaceuticals to Host Zanidatamab KOL Investor Webcast on June 2, 2023
Shubham Pant, M.D., MBBS, a professor in the Department of Gastrointestinal Medical Oncology with a joint appointment in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, will provide an overview of new data from the trial and Jazz senior management will discuss the development and commercialization of zanidatamab. Shubham Pant, M.D., MBBS, a professor in the Department of Gastrointestinal Medical Oncology with a joint appointment in…
PR Newswire
25/05/2023
Transactions in Zealand Pharma shares and/or related securities by persons…
Company announcement – No. 23 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, May 25, 2023–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or...
Nasdaq GlobeNewswire
25/05/2023
Inventiva announces that its partner Sino Biopharm received IND approval from…
Chia Tai Tianqing Pharmaceutical Group Co., Ltd., a Sino Biopharm's subsidiary, receives IND approval from the NMPA to initiate the clinical development in mainland China of lanifibranor in NASHSino Biopharm will participate in the ongoing NATiV3 Phase III trial which, if positive, is expected to support a potential NDA filing in ChinaIn parallel, Sino Biopharm will conduct a Phase I clinical pharmacology studyFollowing this regulatory decision, Inventiva is eligible to the first of the...
Nasdaq GlobeNewswire
25/05/2023
Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel…
Regulated InformationTop-line Data Anticipatedin Q4 2023 Leuven, BELGIUM, Boston, MA, US –May 25 , 2023 – 9:00 pm CET– Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing...
Nasdaq GlobeNewswire
25/05/2023
Healthcare Predictive Analytics Market Size Will Surpass $30.71 Bn by 2028, The…
Browse In-Depth TOC on Healthcare Predictive Analytics Market137 – Tables123 – Charts309 – Pages Browse In-Depth TOC on Healthcare Predictive Analytics Market137 – Tables 123 – Charts 309 – Pages Healthcare costs have surged, and the COVID-19 pandemic has accelerated the inflation of healthcare expenses worldwide. Limited access to quality healthcare due to financial constraints is prevalent in low- and middle-income countries (LMICs). COVID-19 has expedited various existing and emerging...
PR Newswire
25/05/2023
Mithra's General Meeting Of Shareholders Approves the Renewal of its Board of…
Mithra's General Meeting Of Shareholders Approves the Renewal of its Board of DirectorsLiege, Belgium ,25 MAY 2023– 5:45 CEST– Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, today announces that at its Annual General Meeting, held today the appointment/renewal of the following Directors for a two-year mandate was approved. The Board of Directors is now made up of 6 members with varied backgrounds spanning both the financial and...
Nasdaq GlobeNewswire
25/05/2023
Press Release: Annual General Meeting of May 25, 2023 – Frédéric Oudéa new…
Annual General Meeting of May 25 , 2023 –Frédéric Oudéa new Chairman of the Board of DirectorsApproval of the financial statements for the fiscal year 2022Distribution of a cash dividend of €3.56 per share, with payment as of June 1 st, 2023Board composition: Frédéric Oudéa becomes Independent Director and Chairman of the BoardParis,May25 , 2023. The Combined General Shareholders' Meeting of Sanofi was held on May 25, 2023, under the chairmanship of...
Nasdaq GlobeNewswire
25/05/2023
Sequana Medical announces results of Annual General Meeting of Shareholders
PRESS RELEASE REGULATED INFORMATION25 May 2023,06:00pmCESTGhent, Belgium – 25 May 2023– Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that all proposed resolutions submitted to the Annual General Meeting of Shareholders were approved at the meeting held today at 09:00 am CEST.The items...
Nasdaq GlobeNewswire
25/05/2023
Vivoryon Therapeutics Launches Capital Increase by Way of an Accelerated…
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR FORM AN OFFER FOR SALE OF, OR THE SOLICITATION OF AN OFFER TO BUY, THE SECURITIES REFERRED TO HEREIN IN ANY JURISDICTION, INCLUDING THE UNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA, JAPAN OR ANY OTHER...
Nasdaq GlobeNewswire
25/05/2023
Mithra's General Meeting Of Shareholders Approves the Renewal of its Board of…
Liege, Belgium, 25 MAY 2023 – 5:45 CEST– Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, today announces that at its Annual General Meeting, held today all agenda items put to vote were approved, including the appointment of Directors for a two-year mandate. The Board of Directors is now made up of 7 members with varied backgrounds spanning both the financial and pharmaceutical sectors, bringing extensive expertise to Mithra covering all aspects of pharmaceutical...
Nasdaq GlobeNewswire
25/05/2023
LBB Specialties Announces Headquarters Relocation
LBB Specialties will occupy the first floor of 601 Merritt 7. LBB Specialties will occupy the first floor of 601 Merritt 7. "We are thrilled to be relocating to Merritt 7 and consolidating ourConnecticutoffices to a single top-tier business environment," saidMaryellen Meehan, LBBS chief human resources officer. "The abundance of new amenity space, including multiple indoor-outdoor recreation, meeting, and event spaces were critical in our decision. The management team brings...
PR Newswire
25/05/2023
Idiopathic Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 80+…
Key Takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report Request a sample and discover the recent advances in idiopathic pulmonary fibrosis drug treatment @Idiopathic Pulmonary Fibrosis Pipeline Report The idiopathic pulmonary fibrosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage idiopathic pulmonary fibrosis drugs, inactive and dormant assets, a comprehensive assessment of driving...
PR Newswire
25/05/2023
Global Tampon Market Size is Examining the CAGR of 10.1% to Grow From $12.0…
Tampon Market: Overview Tampon Market: Overview A tampon is a female hygiene product used during the menstrual period of females for absorbing blood as well as vaginal secretions. Moreover, the product is placed inside the vagina and expands as it soaks menstrual blood. Furthermore, tampon also absorbs natural lubrication & bacteria present in the vagina. The product is cylindrical and is made up of rayon, cotton, or a blend of rayon & cotton apart from synthetic fibers. A few of...
PR Newswire
25/05/2023
Description of the Share Repurchase Program Authorised by the Ordinary General…
Pursuant to Article 241-2 of the AMF General Regulations ( Règlement Général de l'Autorité des marchés financiers ), the purpose of this description is to present the objectives and terms of the Company's share repurchase program approved by the Ordinary General Meeting of 25 May 2023.Securities concerned : shares issued by Inventiva SA. Maximum proportion of capital that may be purchased by the Company : 10%. Maximum number of its own shares that may be acquired by the Company,...
Nasdaq GlobeNewswire
25/05/2023
Deep Breath Intelligence Teams with HTEC Group and Effectum Medical to…
Considering a very strict regulatory deadline that Deep Breath Intelligence had to meet to make DBI-EPIbreath® compliant, they approached HTEC to help them speed up their product launch considering regulatory requirements of IVDD in conjunction with Effectum Medical AG, the official legal manufacturer of the medical device. Effectum Medical gathered a team of professionals with extensive regulatory and compliance domain knowledge to help HTEC to meet the regulatory requirements for medical…
PR Newswire
25/05/2023
3 World-Renowned Sleep Apnea Experts Present New Benefits of PAP Therapies at…
France's Jean-Louis Pépin and Germany's Holger Woehrle presented studies in which treating OSA with CPAP lowered all-cause mortality for PAP vs. non-PAP users with OSA Germany's Michael Arzt presented new evidence that treating CSA with ASV* caused “a significant and clinically relevant improvement in disease-specific QoL, daytime sleepiness, and quality of sleep”WASHINGTON, May25, 2023(GLOBE NEWSWIRE) -- Renowned medical experts at the American Thoracic Society International...
Nasdaq GlobeNewswire
25/05/2023
Sobi commences tender offer for all outstanding shares of common stock of CTI…
Sobi filed today with the U.S. Securities and Exchange Commission (SEC) a tender offer statement on Schedule TO which sets forth in detail the terms of the tender offer. Additionally, CTI filed with the SEC a solicitation/recommendation statement on Schedule 14D-9 that includes the unanimous recommendation of CTI's board of directors for CTI stockholders to accept the tender offer and tender their shares. Sobi filed today with the U.S. Securities and Exchange Commission (SEC) a tender offer...
PR Newswire
25/05/2023
Tilray Announces European Market Expansion in Italy
Tilray Medical Supports ONCOWELLNESS, Italy's Leading Cancer Research and Patient Care Conference Pharmaidea, a Petrone Group company, to market and educate over 12,000 pharmacies across Italy on the benefits of medical cannabis and medical cannabis patient care. Tilray Medical has an established broad national pharmaceutical distribution network in Italy, where medical cannabis is reimbursed by the healthcare system to eligible patients. Tilray's new medical cannabis authorizations...
Nasdaq GlobeNewswire
25/05/2023
Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary…
Webinar to take place on Monday, June 5, 2023 at 12:30 PM ET TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it will host a virtual KOL event to discuss the potential of foralumab in non-active secondary progressive multiple sclerosis (na SPMS) on Monday, June 5, 2023 at 12:30 PM ET. The event will feature Howard Weiner, M.D. (Co-Director of the Ann Romney Center for...
Nasdaq GlobeNewswire
25/05/2023
Market Study Forecasts CAR-T Cell Therapy Market to reach US$ 7.0 billion by…
Growing prevalence of cancer diseases has given positive impact on target market growth. Approval of CAR-T cell therapies has further, fueled the demand for target market growth. Ongoing research and development activities, and presence of major key players is anticipated to increase demand for CAR-T Cell Therapy market growth over the forecast period. Growing prevalence of cancer diseases has given positive impact on target market growth. Approval of CAR-T cell therapies has further, fueled...
PR Newswire
25/05/2023
Altri Comunicati
